Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381868 | 0.85 | L3MBTL1 (0.66) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL29161535 | 0.85 | L3MBTL1 (0.61) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL30774303 | 0.85 | L3MBTL1 (0.66) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL3641468 | 0.84 | L3MBTL1 (0.69) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL1089156 | 0.84 | L3MBTL1 (0.69) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL11738520 | 0.83 | ALDH1A1 (0.97) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL1772534 | 0.83 | KDM4E (0.71) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL3776763 | 0.82 | SMN1; SMN2 (0.61) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL17565791 | 0.82 | SMN1; SMN2 (0.61) | KDM4EMAPTALDH1A1HPGDGLA | |
| SCHEMBL7324699 | 0.81 | ABCB1 (0.49) | KDM4EMAPTALDH1A1HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854804-B1 | PYRROLIDINO HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9540384-B2 | Pyrrolidino heterocycles | HOFFMANN-LA ROCHE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9115092-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ASANA BIOSCIENCES, LLC (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2854804-A1 | PYRROLIDINO HETEROCYCLES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ASANA BIOSCIENCES, LLC (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2013178569-A1 | PYRROLIDINO HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8440662-B2 | Substituted quinazoline and pyrido-pyrimidine derivatives | ENDO PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| EP-0535104-B1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-09-04 | — | — | EP | disclosed |
| US-5371080-A | Central nervous system disorders | NOVO NORDISK A/S | 1994-12-06 | — | — | US | disclosed |
| US-5276028-A | Psychological disorders, anticonvulsants, anxiolytic or hypnotics and cognition activators | NORDISK A/S (DK) | 1994-01-04 | — | — | US | disclosed |
| EP-0535104-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992000298-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-01-09 | — | — | WO | disclosed |
| US-4048312-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-3956495-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073782-A1 | Substituted Quinazoline and Pyrido-Pyrimidine Derivatives | MTOR, PIK3CA, PDPK1 | KDM4E 739/4885MAPT 3544/4885ALDH1A1 3589/4885 |
| US-20130190492-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | KDM4E 739/4885MAPT 3544/4885ALDH1A1 3589/4885 |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | PDE3A, PDE3B, PDE2A | KDM4E 1810/4885MAPT 4639/4885ALDH1A1 159/4885 |
| US-20150011547-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES | MTOR, PIK3CA, PDPK1 | KDM4E 739/4885MAPT 3544/4885ALDH1A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.